Zymedi Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 27

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $15M

  • Investors
  • 8

Zymedi General Information

Description

Developer of novel therapeutics platform intended to improve the quality of life of people suffering from diseases. The company's platform focuses on aminoacyl-tRNA synthetases (ARSs), pulmonary arterial hypertension, and liver fibrosis, enabling patients to begin treatment more quickly, resulting in a better medical outcome.

Contact Information

Website
www.zymedi.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Posco Green Building (Building 511)
  • 85 Songdokwahak-ro, Yeonsu-gu
  • Incheon, 21983
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Posco Green Building (Building 511)
  • 85 Songdokwahak-ro, Yeonsu-gu
  • Incheon, 21983
  • South Korea
+82

Zymedi Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Zymedi Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A) 30-May-2023 $15M Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 26-Mar-2021 Completed Pre-Clinical Trials
1. Angel (individual) 01-Oct-2020 Completed Pre-Clinical Trials
To view Zymedi’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Zymedi Patents

Zymedi Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4261279-A1 Novel fragmented crs peptide exhibiting immune enhancement activity, and use thereof Pending 10-Dec-2020
JP-2024526483-A Novel crs fragment peptide having immune enhancing activity and use thereof Pending 10-Dec-2020
EP-4261279-A4 Novel fragmented crs peptide exhibiting immune enhancement activity, and use thereof Pending 10-Dec-2020
JP-2022500051-A An antibody that specifically binds to the n-terminal region of lysyl-trna synthase exposed in the outer cell membrane. Active 17-Sep-2018
AU-2019341266-A1 Antibody for specifically binding to lysyl-trna synthetase n-terminal domain exposed to extracellular membrane Active 17-Sep-2018 C07K16/40
To view Zymedi’s complete patent history, request access »

Zymedi Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Zymedi Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Atinum Investment Venture Capital Minority
CKD Venture Capital Corporate Venture Capital Minority
Korea Development Bank Investment Bank Minority
Korea Venture Investment Fund of Funds Minority
Medytox Venture Investment Corporate Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

Zymedi FAQs

  • When was Zymedi founded?

    Zymedi was founded in 2019.

  • Where is Zymedi headquartered?

    Zymedi is headquartered in Incheon, South Korea.

  • What is the size of Zymedi?

    Zymedi has 27 total employees.

  • What industry is Zymedi in?

    Zymedi’s primary industry is Drug Discovery.

  • Is Zymedi a private or public company?

    Zymedi is a Private company.

  • What is Zymedi’s current revenue?

    The current revenue for Zymedi is .

  • How much funding has Zymedi raised over time?

    Zymedi has raised $31.8M.

  • Who are Zymedi’s investors?

    Atinum Investment, CKD Venture Capital, Korea Development Bank, Korea Venture Investment, and Medytox Venture Investment are 5 of 8 investors who have invested in Zymedi.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »